newsfilter
← Latest News
GlobeNewswire·

PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026

PYPD
  • PolyPid Ltd. will present an oral presentation titled "D-PLEX₁₀₀ Lowers the Microbial Burden Without Selecting for Multidrug-Resistant Bacteria" at IDWeek 2026 on Thursday, October 22, 2026, in Washington, D.C.
  • The presentation features an exploratory pooled analysis of microbiology data from the SHIELD I, SHIELD II, & D-PLEX₁₀₀ phase 2 trials involving 2,185 patients.
  • Findings from 134 patients with culture-positive surgical-site infections showed heavy bacterial growth was less frequent in the D-PLEX₁₀₀ arm (16%) compared to standard of care (27%) with a p-value of 0.034.
  • Breakthrough surgical-site infections occurred later in the D-PLEX₁₀₀ group with a median onset of 10.0 days versus 6.5 days for the standard of care group (p<0.001).
  • The proportions of multidrug-resistant organisms were similar between treatment groups, with no statistically significant difference in doxycycline resistance.
  • No statistically significant differences were observed in non-wound infections, systemic antibiotic use, or inflammation across the pooled study population.
  • George M. Viola, M.D., M.P.H. from the University of Texas MD Anderson Cancer Center will deliver the presentation, with co-authors Nurit Tweezer-Zaks, M.D., M.B.A., & Meidan Dvir, Ph.D.
  • D-PLEX₁₀₀ is PolyPid's lead product candidate utilizing the Kynatrix™ delivery technology to provide controlled release of doxycycline for 30 days at the surgical site.
  • The drug received Breakthrough Therapy designation from the FDA for preventing surgical-site infections in patients undergoing elective colorectal surgery.
  • The presentation abstract will be available on www.polypid.com following the conclusion of the conference.